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Highlights 
 Antibiotic dosing in continuous renal replacement therapy in ICU patients 
is highly challenging. 
 Over one-third of patients had concentrations outside the therapeutic 
range. 
 24% of therapeutic drug monitoring (TDM) results manifested 
unnecessarily high antibiotic concentrations. 
 TDM is useful for ensuring optimised dosing. 
 Hospital-acquired pneumonia patients had the highest rates of excessive 
antibiotic concentrations. 
ABSTRACT 
The objective of this study was to describe the effect of therapeutic drug monitoring 
(TDM) and dose adjustments of -lactam antibiotics administered to critically ill 
patients undergoing continuous renal replacement therapy (CRRT) in a 30-bed 
tertiary intensive care unit (ICU). -Lactam TDM data in our tertiary referral ICU were 
retrospectively reviewed. Clinical, demographic and dosing data were collected for 
patients administered -lactam antibiotics while undergoing CRRT. The target trough 
concentration range was 1–10 the minimum inhibitory concentration (MIC). A total 
of 111 TDM samples from 76 patients (46 male) with a mean ± standard deviation 
age of 56.6 ± 15.9 years and weight of 89.1 ± 25.8 kg were identified. The duration 
of antibiotic therapy was between 2 days and 42 days. TDM identified a need for 
dose modification of -lactam antibiotics in 39 (35%) instances; in 27 (24%) samples, 
TDM values resulted in decreasing the prescribed dose of -lactam antibiotic 
whereas an increase in the prescribed dose occurred in 12 (11%) cases. In patients 
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treated for hospital-acquired pneumonia and primary or secondary bacteraemia, the 
dose was required to be decreased in 10/25 (40%) and 7/46 (15%) cases, 
respectively, to attain target concentrations. -Lactam TDM is a useful tool for 
guiding drug dosing in complex patients such as those receiving CRRT. Although 
over one-third of patients manifested concentrations outside the therapeutic range, 
most of these CRRT patients had excessive -lactam concentrations. 
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1. Introduction 
Antibiotic dosing in critically ill patients has been increasingly studied in recent years 
as many antibiotics display severely altered pharmacokinetics in this patient 
population [1]. Drug and patient factors associated with altered pharmacokinetics in 
critically ill patients include the hydrophilicity of the antibiotic, use of invasive 
procedures and devices in the intensive care unit (ICU), organ dysfunction and 
fluctuating fluid balance [1]. Antibiotics are commonly prescribed in the critical care 
setting [2] for the treatment or prophylaxis of infection. There is currently a dearth of 
information available for dosing antibiotics in critically ill patients given the extreme 
heterogeneity of this patient population. Therefore, prescribers are often required to 
extrapolate data from existing studies when selecting an antibiotic dosing regimen 
for individual critically ill patients. The number of factors that need to be considered 
for potential effects on antibiotic dosing in critically ill patients receiving renal 
replacement therapy (RRT) further increases. Indeed, RRT is indicated for a variety 
of conditions in critically ill patients, such as acute kidney injury, fluid overload, 
metabolic acidosis, electrolyte disturbances and drug overdose. RRT introduces a 
largely unquantified effect on -lactam concentrations. 
 
Therapeutic drug monitoring (TDM) of -lactam antibiotics has been proposed as an 
intervention to optimise dosing, particularly in critically ill patients. TDM that 
measures the unbound concentration of the -lactam can guide dose adjustment 
which can ensure free (unbound) concentrations above the minimum inhibitory 
concentration (MIC) of the causative pathogen. Indeed, maximum bactericidal 
activity is believed to occur when -lactam antibiotic concentrations are maintained 
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above the MIC for a specified amount of time; the percentage of time required 
(%fT>MIC) for this to occur is 40%, 50% and 60–70% for carbapenems, penicillins and 
cephalosporins, respectively [3]. The clinical rationale of TDM is to minimise the 
incidence of subtherapeutic and supratherapeutic drug concentrations with the aim 
of improving treatment success and minimising drug toxicity, respectively. 
 
The aim of this study was to describe the effect of TDM and dose adjustments of -
lactam antibiotics administered to critically ill patients undergoing continuous RRT 
(CRRT). 
 
2. Materials and methods 
2.1. Patients 
Patients prescribed -lactam antibiotics in our unit are routinely sampled up to four 
times weekly as part of the -lactam TDM programme. Therefore, data were 
prospectively collected in consecutive patients requiring -lactam antibiotic treatment 
in our 30-bed non-cardiac tertiary adult ICU. From February 2009 until December 
2011, data from all patients aged 18 years undergoing CRRT in whom TDM 
samples were obtained for piperacillin/tazobactam (TZP), meropenem, 
benzylpenicillin, ampicillin, flucloxacillin and ceftriaxone were reviewed. Patients 
were evaluated regardless of antibiotic indication but must have been undergoing 
CRRT at the time of antibiotic administration and were expected to remain on CRRT 
for the following 48 h. Exclusion criteria included expected antibiotic cessation within 
24 h of identification of expected sampling. Ethical approval for data collection was 
granted by the Ethics Committee of Royal Brisbane and Women’s Hospital 
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(Brisbane, QLD, Australia), and the need for informed consent was waived in view of 
the retrospective nature of the data analysis of the prospectively completed 
database. 
 
2.2. Sampling 
Blood samples were taken immediately before re-dosing to determine trough 
concentrations of the antibiotic at steady-state, defined as prior administration of four 
consecutive doses. Steady-state samples were collected to avoid incorrect 
interpretation of results in which the distribution kinetics of the antibiotic may have 
provided a misleadingly low concentration. Total blood concentrations and free 
unbound drug concentrations were measured by the hospital Pathology Department 
and were made available for clinical review within 8 h of collection as previously 
described [4]. Determination of unbound -lactam antibiotic concentrations, including 
the chromatographic system, solutions and sample preparation used at our 
institution, have been previously described in a report by Briscoe et al. [5]. 
 
2.3. Therapeutic drug monitoring targets 
The pharmacodynamic targets for -lactam antibiotics have been defined in in vitro 
and animal models to be unbound concentrations above the MIC of the infective 
bacteria for 40–70% of the dosing interval [6]. For convenience and to increase 
feasibility, an unbound drug concentration above the MIC for 100% of the dosing 
interval is the most common target of treatment for -lactam TDM programmes and 
is also used in our institution [7]. Dose decreases were performed when the unbound 
trough concentration was >10 MIC. 
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 2.4. Continuous renal replacement therapy 
Continuous venovenous haemodiafiltration (CVVHDF) is the most commonly applied 
form of CRRT in our ICU. During the data collection period, CRRT was initiated as a 
standard of care using an Aquarius (Edward Life Sciences, Sydney, NSW, Australia) 
RRT machine. Vascular access was achieved using a double-lumen catheter in the 
internal jugular or femoral vein. The haemodiafilter was a hollow-fibre high-flux AN69 
Nephral ST 200 (Gambro Lundia AB, Lund, Sweden) polyacrylonitrile and sodium 
methallyl sulfonate copolymer filter with a surface area of 1.05 m2. The dialysate and 
replacement fluid used was lactate-free Hemosol BO (Gambro Lundia AB). The 
CRRT circuit was anticoagulated with unfractionated heparin or regional sodium 
citrate. 
 
2.5. Susceptibility data 
-Lactam concentrations were compared with the susceptibility of the known or 
suspected pathogen. Where identified, the MIC of the pathogen was provided as 
determined using VITEK®2 (bioMérieux, Durham, NC). Where the MIC for an 
individual pathogen was not available, susceptibility breakpoints were obtained from 
the European Committee on Antimicrobial Susceptibility Testing (EUCAST). If no 
organism was isolated for a patient, the susceptibility of the potential pathogen was 
based on local bacterial epidemiology, and the highest MIC in the susceptible range 
was selected as the dosing target. Patients admitted for >48 h prior to developing 
symptoms indicative of a bacterial infection were deemed to have nosocomial 
infection. 
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 2.6. Statistical analysis 
Various data relating to demographics, clinical characteristics, microbiology, CRRT 
and clinical outcome were collected. Descriptive statistics were used to describe the 
patient sample, with data presented as the mean ± standard deviation and range. 
Where appropriate, percentages are used to describe the data. 
 
3. Results 
3.1. Patients 
A total of 76 patients met the inclusion criteria for this study (30 female and 46 male), 
with 111 TDM samples collected. The mean age of the patients was 56.6 ± 15.9 
years (range 21–86 years) with a mean weight of 89.1 ± 25.8 kg (range 36–175 kg). 
The mean serum creatinine concentration was 205.2 ± 120.3 mol/L and the mean 
duration of antibiotic therapy was 7 ± 6 days (range 2–42 days). The demographic 
data of the patients are listed in Table 1. Two patients received multiple drug dose 
changes, one patient received two consecutive dose decreases, whilst another 
patient received three consecutive dose increases following TDM. In the study 
population, 38% (29/76) of patients had bacteraemia as the source of infection, with 
hospital-acquired pneumonia (29%; 22/76), abdominal sepsis (13%; 10/76) and 
urosepsis (8%; 6/76) being the other most common indications for therapy. 
Modification of the antibiotic dose based on indication is presented in Table 2. The 
antibiotic dose from which the TDM concentration was measured and the need for 
subsequent dose adjustment is shown in Table 3. The mortality data of patients who 
died during treatment with the study antibiotics and the number of micro-organisms 
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identified and not identified based on clinical diagnosis are presented in Table 4 and 
Table 5, respectively. There were no documented adverse events during the course 
of this retrospective study. 
 
3.2. Continuous renal replacement therapy 
TDM samples were collected during 111 episodes of CVVHDF. In four of these 
episodes the CRRT settings were changed during treatment, with the patients 
undergoing periods of continuous venovenous haemofiltration (CVVH). Post-dilution 
was the primary fluid replacement setting used during study data collection, 
accounting for 107 (96%) episodes, whilst pre-dilution was used in 9 (8%) episodes 
and 5 (5%) treatments used both pre- and post-dilution. The CRRT modes and 
settings reported in Table 1 show the standard CVVHDF settings during TDM 
sampling used a blood flow rate of 200 mL/min, a dialysis flow rate of 1000 mL/h, an 
ultrafiltration rate of 150 mL/h, a post-dilution rate of 1000 mL/h and, when used, a 
pre-dilution rate of 1000 mL/h. 
 
3.3. Dose adjustment data 
Over the data collection period, TDM values required 27 (24%) dose decreases, 12 
(11%) dose increases and maintenance of the current antibiotic dosing regimen in 72 
patients (65%). Table 3 displays the antibiotic dosing regimen administered to the 
patient and the subsequent dose adjustment upon availability of the TDM result. 
 
When considering antibiotic dosing regimens by indication for therapy, for 
bacteraemia, abdominal sepsis and skin and soft -tissue infections no dose 
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adjustment was required based on the majority of TDM samples obtained. In 
contrast, TDM targets demonstrated the need to increase the antibiotic dose in 
hospital-acquired pneumonia in 5 (20%) cases whilst decreasing the antibiotic dose 
in 10 (40%) of that same patient population. 
 
3.4. -Lactam treatment failures 
Eighteen deaths occurred in this cohort of patients during treatment with the 
prescribed antibiotics (Table 5). The duration of -lactam therapy in this patient 
group ranged from 2–10 days. Of note, the admission diagnosis for the majority of 
these patients was not due to an infectious aetiology but was the result of an acute 
or chronic deteriorating health condition with an associated progressive morbidity. 
 
4. Discussion 
In this study, we found that antibiotic dose adjustment was indicated in 39 (35%) 
patients presumed to be at pharmacokinetic ‘steady-state’. Indeed, this is a 
significant proportion of patients in this single-centre study and supports the further 
need, first, to describe innovative individualised approaches to antibiotic dosing that 
can improve the achievement of therapeutic concentrations. Second, this study also 
supports the conduct of clinical studies that evaluating whether dose optimisation of 
-lactams to achieve target concentrations results in improved patient outcomes. 
 
-Lactam antibiotics display time-dependent characteristics in which optimal 
bacterial killing occurs when the free drug concentration remains above the MIC 
(fT>MIC) of the bacteria at the site of infection throughout the dosing interval [8]. Some 
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clinical data support even higher exposures of concentrations that are 4–5 MIC. In 
the current study, 72 TDM samples (65%) achieved the pre-defined pharmacokinetic 
targets, suggesting that the same dose could be maintained until subsequent TDM 
sampling or patient monitoring showed otherwise. Interestingly, almost one-quarter 
of TDM values reported (27/111; 24%) required a decrease of the -lactam antibiotic 
dose; 14 (52%) of those dose decreases occurred for TZP when dosed at 4.0/0.5 g 
every 6 h or 4.0/0.5 g every 8 h. TZP in these cases was indicated to treat infection 
with Pseudomonas aeruginosa or an Enterobacteriaceae with MICs of 16 mg/L or 8 
mg/L, respectively. Despite the relatively high MICs, TZP dramatically exceeded the 
target concentration. Beumier et al. described the differences in -lactam antibiotic 
concentrations during the later treatment phase during CRRT in which -lactam 
antibiotics demonstrated higher TDM concentrations in their study [9]. Furthermore, 
TDM values reported for drugs with high protein binding (flucloxacillin and 
ceftriaxone) suggested the need to decrease or increase the dose in three episodes 
(21%) (Table 3). The pharmacokinetics of these antibiotics in critically ill 
hypoalbuminaemic patients have been described elsewhere [10,11]. A review by 
Jamal et al. concluded that clearance of piperacillin, meropenem and vancomycin 
positively correlated with effluent flow rate [12]. Whilst highly protein bound 
antibiotics were not included in the review by Jamal et al., it is plausible that the 
nature of the chemical interactions that facilitate protein–antibiotic binding may affect 
the amount of bound drug that is removed during RRT, as described by other 
researchers [12,13]. 
 
Dosing of -lactam antibiotics in critically ill patients poses many challenges as both 
the volume of distribution and clearance of hydrophilic drugs, including -lactams, 
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may be affected. Critically ill patients undergoing CVVHDF provide further 
challenges in dosing owing to the paucity of information available as well as 
variability in CVVHDF settings, membrane filter material and filter size. The fluid 
volume status of the patient further complicates this, as CVVHDF in many cases is 
aimed at removing excess fluid from the patient thereby decreasing the volume of 
fluid in which hydrophilic drugs are distributed. As euvolaemia is restored in 
hypervolaemic patients, the volume in which -lactam antibiotics disperse may be 
reduced thereby potentially raising the plasma concentration of the drug. The rate at 
which CRRT corrects fluid volumes in relation to time and the subsequent effect on 
antibiotic pharmacokinetics remains largely unknown. This concept is also 
problematic when prescribing -lactam antibiotics in RRT other than CRRT. The 
CVVHDF settings in our patient group displayed some variation in which flow rates of 
dialysis, ultrafiltrate and post-dilution were modified during a patient’s treatment to 
meet the clinical need. In a retrospective analysis of TDM in ICU patients undergoing 
CRRT, Beumier et al. showed that -lactam drug clearance was positively correlated 
with intensity (mL/kg/h) of CRRT, and the T>MIC was lower in patients with high 
CRRT intensity [9]. These authors also showed that antibiotic concentrations were 
also higher at >5 days of therapy compared with those at 2 days, which may in part 
support the hypothesis of higher concentrations with fluid removal over time. 
 
Trotman et al. suggested dosing meropenem at 1 g every 12 h during CVVH or 
CVVHDF [14]. A previous study by Seyler et al. found that this dose was inadequate 
in reaching target their chosen pharmacodynamic targets for bacteria with an MIC > 
1 mg/L in critically ill patients [15]. Only three of our patients received this dose, with 
most receiving 500 mg every 8 h. Indeed, this smaller but more frequent dose of 
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meropenem very consistently achieved our chosen pharmacodynamic targets, which 
was specific to an MIC of 2 mg/L. 
 
Patients receiving TZP provided the largest number of TDM samples (53/111; 48%), 
and when TZP was dosed at 4.0/0.5 g every 8 h no patients required a dose 
increase. These results are similar to those described by Awissi et al. in which TZP 
was administered as a 4-h infusion in 20 critically ill patients receiving CVVHDF [16]. 
The authors of that study found piperacillin fT>MIC for P. aeruginosa (MIC of 64 mg/L) 
occurred in 18 patients for 50% of the dosing interval. This result contrasts with that 
from Seyler et al. who reported failure to attain concentrations for higher MICs with 
TZP doses 4.0/0.5 g every 6 h in critically ill patients undergoing CRRT [15]. The 
differences in observations between studies may be attributed to differences in the 
critically ill patient population and demographics [17], residual renal function, method 
of drug administration, fluid status, CRRT settings, membrane material and size, 
indication for antibiotic and CRRT, and study size. 
 
This study has limitations. First, the prescription of CVVHDF was suited to meet the 
clinical needs of the individual patient. This included changes in the flow rates of the 
blood, ultrafiltrate, dialysate and pre/post-dilution fluid. It follows that pharmacokinetic 
variability of antibiotics may exist due to the heterogeneity of critically ill patients and 
CRRT settings, although this is the scenario clinically. Second, in patients in whom 
an infective organism was not identified, the target concentrations were based on the 
susceptibility of the most likely infective pathogen. The target MIC was therefore 
based on information from the local antibiogram for the institution and as such higher 
target concentrations than may have actually been necessary were used. Third, 
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TDM values were reported up to 8 h following blood collection. This occurs as the 
chromatography method used to determine -lactam concentrations is more time 
consuming compared with the immunoassay methods used to measure 
aminoglycoside and glycopeptide concentrations. Despite the delay, we consider this 
timing for data interpretation and potential dose adaptation rarely exceeded one 
dosing interval. Fourth, blood samples provide a surrogate marker for -lactam 
antibiotics and may differ from concentrations of the antibiotic at the site of infection. 
Blood samples, however, are readily analysable and the unbound concentration of 
the antibiotic is likely to correlate with similar concentrations at the site of infection in 
most patients [4]. 
 
Given that -lactam antibiotics have no ‘end of needle’ effect where no immediate 
clinical effect of therapy is readily observable, TDM appears to be attractive as a tool 
to determine whether current dosing is achieving therapeutic concentrations and 
provide subsequent dosing guidance. We were able to determine from TDM values 
reported in our CRRT patient group the need to maintain, increase or decrease -
lactam antibiotic levels in 72 (65%), 12 (11%) and 27 (24%) doses, respectively. 
When available, TDM should be used to titrate -lactam antibiotic therapy in critically 
ill patients in an effort to improve patient outcomes. A definitive study of the clinical 
outcomes benefits of -lactam TDM is required. 
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Table 1. Demographic data and continuous venovenous haemodiafiltration 
(CVVHDF) settings of 76 patients 
 Mean ± S.D. a Range 
Male/female (n) 46/30  
Age (years) 56.6 ± 15.9 21–86 
Weight (kg) 89.1 ± 25.8 36–175 
SCr (mol/L) 205.2 ± 120 36–711 
Duration of antibiotic therapy (days) 7 ± 6 2–42 
CVVHDF settings 
Qb (mL/min) 192 ± 22 150–250 
Qd (mL/h) 1346 ± 524 1000–3000 
Qf (mL/h) 144 ± 110 0–1000  
Post-dilution rate (mL/h) 1532 ± 739 50–3375 
Pre-dilution rate (mL/h) 1222 ± 441 1000–2000 
S.D., standard deviation; SCr, serum creatinine; Qb, blood flow rate; Qd, dialysate 
flow rate; Qf, ultrafiltrate flow rate. 
a Data are mean ± S.D. unless otherwise stated. 
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Table 2. Effect of indication for antibiotic therapy on the need for -lactam antibiotic 
dose adjustment at the first therapeutic drug monitoring (TDM) level 
Indication for antibiotic 
therapy 
TDM 
samples 
Dose 
maintained 
Dose 
increased 
Dose 
decreased 
Primary or secondary 
bacteraemia 
46 (41%) 35 (76%) 4 (9%) 7 (15%) 
Hospital-acquired 
pneumonia 
25 (23%) 10 (40%) 5 (20%) 10 (40%) 
Community-acquired 
pneumonia 
1 (1%) 0 (0%) 0 (0%) 1 (100%) 
Wound prophylaxis post-
trauma or post-operative 
4 (4%) 1 (25%) 0 (0%) 3 (75%) 
Meningitis 2 (2%) 1 (50%) 1 (50%) 0 (0%) 
Skin and soft-tissue 
infection 
4 (4%) 3 (75%) 0 (0%) 1 (25%) 
Abdominal sepsis 18 (16%) 16 (89%) 0 (0%) 2 (11%) 
Neutropenic sepsis 3 (3%) 3 (100%) 0 (0%) 0 (0%) 
Urosepsis 8 (7%) 3 (38%) 2 (25%) 3 (38%) 
Total 111 
(100%) 
72 (65%) 12 (11%) 27 (24%) 
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Table 3. -Lactam dose adjustments based on therapeutic drug monitoring (TDM) value for individual drugs in critically ill patients 
(n = 76) during continuous venovenous haemodiafiltration 
Antibiotic Standard initiation dose TDM samples Dose maintained Dose increased a Dose decreased b 
TZP 4.5 g q6h 9 2 (22%) 1 (11%) 6 (67%) 
4.5 g q8h 37 29 (78%) – 8 (22%) 
4.5 g q12h 7 4 (57%) 2 (29%) 1 (14%) 
Ampicillin 1 g q6h 1 – – 1 (100%) 
Meropenem 0.5 g q6h 5 5 (100%) – – 
0.5 g q8h 17 13 (76%) 1 (6%) 3 (18%) 
0.5 g q12h 1 – 1 (100%) – 
1 g q6h 2 1 (50%) 1 (50%) – 
1 g q8h 10 5 (50%) 2 (20%) 3 (30%) 
1 g q12h 3 1 (33%) 1 (33%) 1 (33%) 
Penicillin G 1.2 g q4h 1 – – 1 (100%) 
1.8 g q4h 2 – 1 (50%) 1 (50%) 
1.8 g q6h 2 1 (50%) – 1 (50%) 
Flucloxacillin 1 g q4h 1 – 1 (100%) – 
1 g q8h 1 – 1 (100%) – 
2 g q6h 7 7 (100%) – – 
Ceftriaxone 1 g q12h 4 4 (100%) – – 
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2 g q12h 1 – – 1 (100%) 
Total   111 72 (65%) 12 (11%)  27 (24%) 
TZP, piperacillin/tazobactam; q6h, every 6 h; q8h, every 8 h; q12h, every 12 h; q4h, every 4 h. 
a Includes increased dosing frequency or increased dose. 
b Dose adjustment for TZP was based on piperacillin concentrations only. 
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Table 4. Mortality data for patients (n = 18) who died during -lactam therapeutic drug monitoring (TDM) 
Patient Sex Age 
(years) 
Weight 
(kg) 
SCr 
(mg/L) 
Duration of 
therapy 
(days) 
Admission diagnosis/reason for antibiotic TDM details 
1 F 29 61 31 3 GvHD with respiratory, skin and GIT 
involvement; respiratory failure 
Meropenem for MSSA (MIC = 
2mg/L), fCmin = 3 MIC 
2 M 68 91 354 7 Hypoxic brain injury secondary to 
pulseless electrical activity following 
cardiac arrest; VAP 
TZP for Enterobacteriaceae 
(MIC = 8 mg/L), fCmin = 5 
MIC 
3 M 70 153 172 4 Pulmonary embolism with DVT; intra-
abdominal sepsis with MODS 
Meropenem for 
Pseudomonas aeruginosa 
(MIC = 2 mg/L), fCmin = 6 
MIC 
4 M 86 116 104 2 Multi-organ failure in the context of 
abdominal sepsis 
Meropenem for 
Enterobacteriaceae (MIC = 
2 mg/L), fCmin = 8 MIC 
5 F 44 60 160 2 Acute liver failure secondary to 
paracetamol overdose; VAP 
TZP for P. aeruginosa (MIC = 
8 mg/L), fCmin >10 MIC 
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6 F 58 80 <30 5 Cholecystitis, Wilson's haemolytic crisis; 
acute liver failure, AKI, rapid AF; sepsis 
Meropenem for 
Enterobacteriaceae, fCmin = 
6 MIC 
7 F 32 36 76 8 Sepsis; cardiac failure secondary to 
cardiac infiltrates in the setting of AML 
Meropenem for empirical 
therapy (MIC = 2 mg/L), 
fCmin >10 MIC 
8 M 70 120 209 3 Multi-organ failure and aortic graft 
infection in context of ruptured 
abdominal aortic aneurysm 
Meropenem for 
Enterobacteriaceae (MIC = 
2 mg/L), fCmin = 5 MIC 
9 M 48 105 138 3 MODS secondary to MSSA sepsis Flucloxacillin for MSSA (MIC 
= 1 mg/L), fCmin >10 MIC 
10 M 66 80 108 2.5 Multi-trauma; circulatory shock 
secondary to LV dysfunction 
TZP for empirical therapy 
(MIC = 16 mg/L), fCmin = 4 
MIC 
11 M 47 80 92 2 Acute liver dysfunction, MODS 
secondary to upper GIT bleed in the 
context of chronic alcoholic liver disease 
TZP for Enterobacteriaceae 
(MIC = 8 mg/L), fCmin >10 
MIC 
12 F 49 79 82 10 Respiratory failure, fluid overload; MODS 
secondary to streptococcal sepsis in the 
context of bone marrow failure post-
transplantation for aplastic anaemia 
TZP for Streptococcus 
salivarius (MIC = 0.5 mg/L), 
fCmin >10 MIC 
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13 M 68 80 59 3 Burns; MODS secondary to P. 
aeruginosa septic shock 
TZP for P. aeruginosa, fCmin 
= 6 MIC 
14 M 77 95 133 6 MODS; ESRF, type II diabetes mellitus, 
cerebellar stroke 
Meropenem for P. 
aeruginosa (MIC = 4 mg/L), 
fCmin = 3 MIC 
15 M 33 61 502 5 CAP (MSSA) and ARDS; bone marrow 
transplant GvHD 
TZP for MSSA (MIC = 2 
mg/L), fCmin >10 MIC 
16 F 64 40 164 6 VAP, ESRF, COAD Meropenem for P. 
aeruginosa (MIC = 2 mg/L), 
fCmin >10 MIC 
17 M 24 86 349 5 VAP, IVDU, hypoxic brain injury TZP for Enterobacteriaceae 
(MIC = 8 mg/L), fCmin = 1 
MIC 
18 F 60 65 78 3 MODS secondary to Escherichia coli UTI 
sepsis in the background of chronic 
alcoholic liver disease; decompensated 
hepatic failure 
TZP for Enterobacteriaceae 
(MIC = 8 mg/L), fCmin >10 
MIC 
SCr, serum creatinine; GvHD, graft-versus-host disease; GIT, gastrointestinal tract; MSSA, methicillin-sensitive Staphylococcus 
aureus; MIC, minimum inhibitory concentration (known or presumed); fCmin, free (unbound) minimum (trough) concentration in a 
dosing interval; VAP, ventilator-associated pneumonia; TZP, piperacillin/tazobactam; DVT, deep vein thrombosis; MODS, multiple 
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organ dysfunction syndrome; AKI, acute kidney injury; AF, atrial fibrillation; AML, acute myeloid leukaemia; LV, left ventricular; 
ESRF, end-stage renal failure; CAP, community-acquired pneumonia; ARDS, acute respiratory distress syndrome; COAD, chronic 
obstructive airways disease; IVDU, intravenous drug user; UTI, urinary tract infection. 
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Table 5. Number of micro-organisms identified and not identified based on clinical 
diagnosis 
Clinical diagnosis Organisms isolated 
Primary or secondary bacteraemia MSSA (7) 
Klebsiella pneumoniae (6) 
Escherichia coli (5) 
Enterobacter cloacae (3) 
Other organism (13) 
Unidentified (12) 
Hospital-acquired pneumonia MSSA (3) 
Pseudomonas aeruginosa (3) 
Other organism (10) 
Unidentified (9) 
Community-acquired pneumonia MSSA (1) 
Meningitis Streptococcus anginosus (1) 
Unidentified (1) 
Wound prophylaxis post-trauma or post-operative Serratia marcescens (1) 
Morganella morganii (1) 
Enterobacter aerogenes (1) 
Streptococcus pyogenes (1) 
Skin and soft-tissue infection S. marcescens (1) 
E. coli (2) 
K. pneumoniae (1) 
Abdominal sepsis Enterococcus faecalis (4) 
E. coli (3) 
Salmonella Typhimurium (1) 
Other organism (6)  
Unidentified (4) 
Neutropenic sepsis Unidentified (3) 
Urosepsis E. coli (4) 
Other organism (3) 
Unidentified (1) 
Total organisms identified 81 (73%) 
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Total organisms not identified 30 (27%) 
MSSA, methicillin-sensitive Staphylococcus aureus. 
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